A comparative analysis of some biochemical parameters of the blood serum in patients with type II diabetes, abdominal obesity and arterial hypertension in the metabolic syndrome

Authors

  • N. V. Melikova Azerbaijan Medical University, Azerbaijan
  • A. M. Efendiev Azerbaijan Medical University, Azerbaijan
  • E. Yu. Akhmedov National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/nphj.19.5

Keywords:

diabetes mellitus, metabolic syndrome, blood

Abstract

Aim. To analyze the changes in the main biochemical parameters in the blood serum in patients with arterial hypertension with abdominal obesity and type II DM and create a reasonable concept for healthcare practitioners for preventing the expected complications.

Materials and methods. 25 patients with diagnosed arterial hypertension with abdominal obesity and type II diabetes mellitus were examined on the background of the metabolic syndrome at the age of 25 to 70 (men and women). To determine the components of carbohydrate, lipid metabolism and free radical oxidation in patients with type II DM with the metabolic syndrome the blood plasma was studied. Blood sampling was carried out from the ulnar vein after a twelve-hour fast. Patients with cardiovascular pathology (hypertension) and type II diabetes were combined into the group “metabolic syndrome” by biochemical characteristics. The parameters of the complete blood count were studied on a Mythic 18 apparatus (Switzerland). The levels of glucose, HbA1, insulin, C-peptide, cholesterol, bChL, aChL, triglycerides, malondialdehyde, SOD, catalase were studied.
Results and discussion. The results of our studies showed that all parameters of the carbohydrate and lipid metabolism significantly changed in the direction of their growth. Compared to the control group in patients with arterial hypertension, abdominal obesity, type II DM the concentration of glucose increased by 156.5 % p < 0.001, the concentration of glucohemoglobin – by 81.2 % (p < 0.001), the concentration of insulin – by 80.9 % (p < 0.001), the C-peptide concentration – by 178.4 % (p < 0.001), cholesterol by – 70.8 % p < 0.001, the bChL concentration – by 71.1 % (p < 0.001), the aChL concentration – by 17.3 %, the concentration of triglycerides – by 178.9 % (p < 0.001), the MDA content – by 302.4 % (p < 0.001), the activity of SOD, the enzyme of the antioxidant system, – by 58.3 % (p < 0.001), catalase – by 98.4 % (p < 0.001), GP – by 80 % (p < 0.001), IL-8 – by 171.8 % (p < 0.001), while the GSH content was reduced by 26.9 % (p < 0.001). All the data obtained and complications are directly related to insulin resistance and hyperinsulinemia.
Conclusions. In the metabolic syndrome accompanied with type II DM, arterial hypertension, and abdominal obesity, the carbohydrate and lipid metabolism is severely impaired. In the metabolic syndrome accompanied by type 2 DM arterial hypertension, abdominal obesity the products of LPO, in particular MDA, increase in the blood, enzymes of the antioxidant system – SOD and catalase are activated, the activity of GSH decreases, while the content of the pro-inflammatory cytokine IL-8 increases.

Author Biographies

N. V. Melikova, Azerbaijan Medical University

senior laboratory assistant of the Biochemistry Department

A. M. Efendiev, Azerbaijan Medical University

Doctor of Biology (Dr. habil), professor of the Biochemistry Department

E. Yu. Akhmedov, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), associate professor of the Analytical Department

References

Makolkin, V. I. (2010). Metabolic syndrome. Moscow : Meditsinskoye informatsionnoye agentstvo, 144 p.

Reaven, G. M. (2006). The metabolic syndrome: is this diagnosis necessary? The American Journal of Clinical Nutrition, 83 (6), 1237–1247. https://doi.org/10.1093/ajcn/83.6.1237

Efremenko, Iu. R. (2011). Klinicheskaia laboratornaia diagnostika, 10, 37–60.

Roitberg, G. E. (Ed.). (2007). Metabolicheskii sindrom. Moscow : MEDpress-inform, 224.

Koroleva, E. F., Efremenko, Iu. R. Efremenko (2011). Sbornik materialov Kh–oi nauchnoi sessii molodykh uchenykh i studentov “Sovremennoe reshenie aktualnykh nauchnykh problem v meditcine”. Nizhny Novgorod, 130.

Kononenko, I. V., Smirnova O. M. (2010). RMZh, 18 (14), 892–896.

Morozova, T. E., Latyipova, E. R. (2013). Consilium medicum, 15 (10), 5–8.

Mustafaeva, A. G. (2017). Azerbaidzhanskii Meditcinskii Zhurnal, 2, 41–45.

Radaeva, M. V. (2008). Aktivnost antioksidantnykh fermentov v norme i pri okislitelnom stresse na primere metabolicheskogo sindroma : avtoref. dis. kand. biol. nauk. Extended abstract of candidate’s thesis. Nizhny Novgorod, 27.

Dedova, I. I., Melnichenko, G. A. (Eds.). (2006). Ozhirenie : etiologiia, patogenez, klinicheskie aspekty. Moscow : MIA, 452.

Olefsky, J. M., & Glass, C. K. (2010). Macrophages, Inflammation, and Insulin Resistance. Annual Review of Physiology, 72 (1), 219–246.

https://doi.org/10.1146/annurev-physiol-021909-135846

Titov, V. N., Shiriaeva. Iu. K. (2011). Klinicheskaia laboratornaia diagnostika, 4, 3–13.

Kurbanov, Ia. Z., Abbasova, M. R., Rzaeva, R. A., Novruzova, M. S. (2016). Azerbaidzhanskii Meditcinskii Zhurnal, 3, 45–51.

Ismailova, G. A. (2016). Azerbaidzhanskii Meditcinskii Zhurnal, 2, 35–39.

Delarue, J., Magnan, C. (2007). Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care, 10 (2), 142–148.

Kisliak, O. A. (2007). Arterialnaia gipertenziia v podrostkovom vozraste. Moscow: Miklosh, 288.

Ye, J. (2007). Role of Insulin in the Pathogenesis of Free Fatty Acid–Induced Insulin Resistance in Skeletal Muscle. Endocrine, Metabolic & Immune Disorders–Drug Targets, 7 (1), 65–74. https://doi.org/10.2174/187153007780059423

Meigs, J. B., Rutter, M. K., Sullivan, L. M., Fox, C. S., D’Agostino, R. B., & Wilson, P. W. F. (2007). Impact of Insulin Resistance on Risk of Type 2 Diabetes and Cardiovascular Disease in People With Metabolic Syndrome. Diabetes Care, 30 (5), 1219–1225. https://doi.org/10.2337/dc06-2484

Downloads

Published

2019-08-21

Issue

No. 2(98) (2019)

Section

Experimental and Clinical Pharmacology

License

Copyright (c) 2019 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).